Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.97 -34.49 -0.83%
Ticker Volume Price Price Delta
STOXX 50 3,175.97 -23.72 -0.74%
FTSE 100 6,674.74 -7.02 -0.11%
DAX 9,544.19 -55.90 -0.58%
Ticker Volume Price Price Delta
NIKKEI 14,415.12 -131.15 -0.90%
TOPIX 1,164.44 -9.37 -0.80%
HANG SENG 22,514.66 5.02 0.02%

CytoSorbents Awarded Additional Phase I Option on US Army SBIR Trauma Contract

CytoSorbents Awarded Additional Phase I Option on US Army SBIR Trauma Contract

MONMOUTH JUNCTION, N.J., April 11, 2013 (GLOBE NEWSWIRE) -- CytoSorbents
Corporation (OTCBB:CTSO), a critical care focused therapeutic device company
using blood purification to treat life-threatening illnesses, today announced
the award of an additional Phase I Option SBIR (Small Business Innovation
Research) contract by the US Army Medical Research and Materiel Command,
valued at $50,000 over a 2 month period. The Phase I Option is intended to
fund program-related interim research and development in advance of finalizing
contract negotiations on the previously announced $1M Phase II SBIR award. The
Phase II SBIR award will fund animal research in trauma and burn injury using
the Company's proprietary CytoSorb® cytokine removal technology.  

This work is supported by the US Army Medical Research and Materiel Command
under an amendment of Contract No W81XWH-12-C-0038.

About CytoSorbents Corporation

CytoSorbents Corporation is a critical care focused therapeutic device company
using blood purification to modulate the immune system and fight multi-organ
failure in life-threatening illnesses. Its purification technology is based on
biocompatible, highly porous polymer beads that can actively remove toxic
substances from blood and other bodily fluids by pore capture and
adsorption. CytoSorb®, the Company's flagship product, is approved in the
European Union as a safe and effective extracorporeal cytokine filter,
designed to reduce the "cytokine storm" that could otherwise cause massive
inflammation, organ failure and death in common critical illnesses such as
sepsis, burn injury, trauma, lung injury, and pancreatitis. CytoSorb® also
removes myoglobin from blood, making it a potential treatment of
rhabdomyolysis in trauma. These are conditions where the mortality is
extremely high, yet no effective treatments exist. Additional information is
available for download on the Company's website:

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for
the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this press
release are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ materially from
those anticipated. These statements are based on management's current
expectations and assumptions and are naturally subject to uncertainty and
changes in circumstances. We caution you not to place undue reliance upon any
such forward-looking statements. Actual results may differ materially from
those expressed or implied by the statements herein. Risk factors are detailed
in the Company's Form 10-K filed with the SEC on April 3, 2013, which is
available at

CONTACT: Company Contact:
         CytoSorbents Corporation
         Dr. Phillip Chan
         Chief Executive Officer
         (732) 329-8885 ext. *823
         Investor Contact:
         Alliance Advisors, LLC
         Alan Sheinwald
         (914) 669-0222
         Valter Pinto
         (914) 669-0222 x201
         Media Contact:
         JQA Partners
         Jules Abraham
         (917) 885-7378
Sponsored Links
Sponsored Links